Literature DB >> 17929832

Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron.

M Nakamura1, N Shishido, Akihiko Nunomura, Mark A Smith, George Perry, Y Hayashi, K Nakayama, T Hayashi.   

Abstract

Zinc, iron and copper are concentrated in senile plaques of Alzheimer disease. Copper and iron catalyze the Fenton-Haber-Weiss reaction, which likely contributes to oxidative stress in neuronal cells. In this study, we found that ascorbate oxidase activity and the intensity of ascorbate radicals measured using ESR spectroscopy, generated by free Cu(II), was decreased in the presence of amyloid-beta (Abeta), the major component of senile plaques. Specifically, the ascorbate oxidase activity was strongly inhibited (85% decrease) in the presence of Abeta1-16 or Abeta1-42, whereas it was only slightly inhibited in the presence of Abeta1-12 or Abeta25-35 (<20% inhibition). Ascorbate-dependent hydroxyl radical generation by free Cu(II) decreased in the presence of Abeta in the identical order of Abeta1-42, Abeta1-16 > Abeta1-12 and was abolished in the presence of 2-fold molar excess glycylhystidyllysine (GHK). Ascorbate oxidase activity and ascorbate-dependent hydroxyl radical generation by free Fe(III) were inhibited by Abeta1-42, Abeta1-16, and Abeta1-12. Although Cu(II)-Abeta shows a significant SOD-like activity, the rate constant for the reaction of superoxide with Cu(II)-Abeta was much slower than that with SOD. Overall, our results suggest that His6, His13, and His14 residues of Abeta1-42 control the redox activity of transition metals present in senile plaques.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17929832     DOI: 10.1021/bi701079z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  53 in total

Review 1.  Cell cycle deregulation in the neurons of Alzheimer's disease.

Authors:  Calvin Moh; Jacek Z Kubiak; Vladan P Bajic; Xiongwei Zhu; Mark A Smith; Hyoung-Gon Lee
Journal:  Results Probl Cell Differ       Date:  2011

Review 2.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

3.  Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

Authors:  Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A Smith
Journal:  Neurosci Lett       Date:  2009-03-25       Impact factor: 3.046

Review 4.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

5.  Capturing a reactive state of amyloid aggregates: NMR-based characterization of copper-bound Alzheimer disease amyloid β-fibrils in a redox cycle.

Authors:  Sudhakar Parthasarathy; Brian Yoo; Dan McElheny; William Tay; Yoshitaka Ishii
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

6.  Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.

Authors:  Afsaneh Porzoor; Joanne M Caine; Ian G Macreadie
Journal:  Prion       Date:  2014       Impact factor: 3.931

Review 7.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 8.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

9.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

10.  Treatment advances in Alzheimer's disease based on the oxidative stress model.

Authors:  Avi L Friedlich; Raj K Rolston; Xiongwei Zhu; Michael W Marlatt; Rudy J Castellani; Akihiko Nunomura; Hyoung-Gon Lee; Gemma Casadesus; George Perry; Mark A Smith
Journal:  F1000 Med Rep       Date:  2009-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.